08:55 AM EST, 02/21/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Friday it was able to stabilize both Silver(I) and the highly reactive Silver(II) in a biologically compatible form with its Telomir-1 compound.

The company said the Telomir-1 compound would help overcome hurdles in silver-based medical applications and open up new possibilities for advanced antimicrobial treatments, wound care, and infection-resistant medical coatings.

The silver-based medical treatments market is rapidly growing, with the silver wound dressings segment valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030, the company said.

Additionally, the company added that the antimicrobial coatings market, which includes silver-infused medical devices, hospital surfaces, and implants, is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031.

Telomir said it is advancing research and development to explore clinical applications of stabilized Silver(II) complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.

Shares of the company rose 5% in recent premarket trading.

Price: 4.40, Change: +0.22, Percent Change: +5.14